Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + Osimertinib in EGFR T790M-positive advanced nonsquamous NSCLC (single-arm, open-label)
ChiCTR2100042664Phase 4Recruiting
- Sponsor
- Taizhou First People's Hospital
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab and osimertinib in non-small cell lung cancer (NSCLC), sponsored by Taizhou First People's Hospital. Primary endpoint: Progression-free survival (PFS). Started Mar 2021; status: recruiting.
02
Drugs
bevacizumabosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100042664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042664.